Effectiveness of benralizumab for allergic and eosinophilic predominant asthma following negative initial results with omalizumab

Daisuke Minami, Hiroe Kayatani, Ken Sato, Keiichi Fujiwara & Takuo Shibayama

Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama City, Okayama, Japan.

Keywords
Allergic, asthma, benralizumab, eosinophilic, omalizumab.

Abstract
A 64-year-old woman, who had presented with a 30-year history of refractory asthma, and been treated with anti-allergic drug therapy, inhaled corticosteroids, a long-acting beta-agonist, and a long-acting muscarinic antagonist. She had been characterized as an allergic, eosinophilic asthmatic. Although omalizumab was tried initially, it was found to be insufficient. We began treatment with benralizumab. The asthma symptom control and sinusitis were improved immediately. Benralizumab was effective for overlapping patient population following negative initial results with omalizumab.

Introduction
Benralizumab is an anti-eosinophil monoclonal antibody against the interleukin-5 (IL-5) receptor. The drug significantly reduces annual exacerbation rates, and improves the forced expiratory volume in 1 second (FEV₁) and asthma symptom control, while being well tolerated. The extent to which the exacerbation rate was reduced increased with the blood eosinophil threshold in a meta-analysis of two studies [1,2]. However, little is known about the effectiveness of this therapy for combined allergic and eosinophilic predominant asthma. We present a patient with both allergic and eosinophilic predominant asthma whose asthma symptom control and sinusitis were improved by benralizumab following negative initial results with omalizumab.

Case Report
A 64-year-old woman presented with a 30-year history of refractory asthma. She had been treated with anti-allergic drug therapy, inhaled corticosteroids (fluticasone propionate 1000 μg/day), a long-acting beta-agonist, and a long-acting muscarinic antagonist. She had occasionally been treated with oral or systemic corticosteroids (oral prednisone 10 mg/day or methylprednisolone sodium succinate 80 mg/day, 3–5 days) for exertional dyspnoea. However, these treatments were all insufficient. She had been characterized as an allergic, eosinophilic asthmatic, with positive results for perennial inhalant allergen sensitivity, allergic rhinitis, and allergic diathesis (egg and sesame) with immunoglobulin E (IgE) and peripheral eosinophil levels of 618 IU/mL and 1006/μL, respectively, and omalizumab was tried initially. However, it was found to be insufficient owing to asthma exacerbation, and she required inpatient treatment 2 months later. In the 16th week following omalizumab, these treatments were not effective for asthma symptom control. If was felt that benralizumab was indicated for eosinophilic predominant asthma.

On physical examination, chest auscultation revealed slight diffuse expiratory wheezing, but the remaining systemic examination did not reveal any significant abnormalities. Her peripheral arterial blood oxygen saturation was 95% on room air. Computed tomography (CT) showed diffuse bronchial wall thickening and paranasal sinusitis (Fig. 1A, B). She had sputum eosinophilia
The eosinophil count was more than 80% in sputum. Laboratory data showed an increase in the number of peripheral eosinophils and IgE level. The blood eosinophil count was 1924/μL and the IgE level was 4123 IU/mL. The patient’s FEV₁ was 1640 mL (%FEV₁, 66.3%) and her vital capacity (VC) was 2400 mL (%VC, 89.0%). The fractional exhaled nitric oxide (FeNO) was 13 ppb (Table 1).

We began treatment with benralizumab. The eosinophil count decreased from 1924 to 0/μL after 2 weeks of treatment. The IgE level decreased from 4123 to 836 IU/mL after benralizumab treatment. Symptom improvement and fewer peripheral eosinophils were observed immediately after beginning benralizumab treatment.

Table 1. Time course of the benralizumab treatment.

|                           | Before benralizumab | After benralizumab for 2 months | After benralizumab for 4 months |
|---------------------------|---------------------|---------------------------------|---------------------------------|
| VC (mL)                   | 2400                | 2490                            | 2490                            |
| %VC (%)                   | 89.0                | 91.7                            | 93.0                            |
| FEV₁ (mL)                 | 1640                | 1760                            | 1630                            |
| FEV₁% (%)                 | 66.3                | 73.3                            | 70.1                            |
| %FEV₁ (%)                 | 80.2                | 85.6                            | 80.7                            |
| FeNO (ppb)                | 13                  | 26                              | 15                              |
| Peripheral eosinophils (count/μL) | 1924              | 0                               | 0                               |
| Immunoglobulin E (IU/mL)  | 4123                | 1853                            | 836                             |
| AQLQ score                | 5.53                | 6.15                            | 6.43                            |

Symptom improvement and fewer peripheral eosinophils were observed immediately after beginning benralizumab treatment.

AQLQ, Asthma Quality of Life Questionnaire; FeNO, fractional exhaled nitric oxide; FEV₁, forced expiratory volume in 1 second; VC, vital capacity.
4 months (Table 1). Moreover, CT showed reduced mucus secretion in the bronchus and paranasal sinus 2 months later (Fig. 1D, E). Eosinophils disappeared from the sputum immediately (Fig. 1F). However, the %VC, %FEV₁, and FeNO did not change between baseline and 4 months following the initiation of benralizumab. The Asthma Quality of Life Questionnaire score improved from 5.53 at baseline to 6.43 4 months after treatment began (Table 1).

Discussion

Only a minority of patients share equal features of both allergic and eosinophilic predominant asthma. In these patients with overlapping phenotypes, the treating physician usually chooses to start with either anti-IgE or anti-IL-5 treatment. In patients with allergic asthma, the baseline blood eosinophil level (≥300/μL) predicts the response to omalizumab. Omalizumab reduces eosinophil numbers in peripheral blood and the airways of asthmatic patients based on clinical and observational studies and case reports [3]. In patients with severe eosinophilic asthma not optimally controlled with omalizumab, when switched to mepolizumab, an anti-eosinophil monoclonal antibody against the IL-5 receptor, there was an improvement in asthma exacerbations, emergency department visits, and hospitalizations [4]. In our case, benralizumab immediately improved the asthma symptom control and sinusitis after a negative initial response to omalizumab. Benralizumab strongly induces antibody-dependent cell-mediated cytotoxicity (ADCC) of eosinophils and basophils [5], and is effective for not only asthma symptom control but also sinusitis. In this overlapping patient population, there is no objective, evidence-based answer to the question “Is anti-IgE or anti-IL-5 the first choice?” A prospective large-scale randomized study comparing these drugs might be of interest.

Disclosure Statement

Appropriate written informed consent was obtained for publication of this case report and accompanying images.

Acknowledgments

The authors thank K. Takada, H. Omori, T. Yonei, and T. Sato for providing helpful discussion.

References

1. Bleecker ER, FitzGerald JM, Chanez P, et al. 2016. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 388:2115–2127.
2. FitzGerald JM, Bleecker ER, Nair P, et al. 2016. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 388:2128–2141.
3. Casale TB, Chipps BE, Rosén K, et al. 2018. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. Allergy 73:490–497.
4. Nair P, Galkin D, Liu MC, et al. 2017. Efficacy and safety of mepolizumab in uncontrolled patients with severe eosinophilic asthma following a switch from omalizumab (OSMO study): exacerbation and safety outcomes. J Allergy Clin. Immunol. 141:2.
5. Wu Y, Akhgar A, Li J, et al. 2018. Selection of a ligand-binding neutralizing antibody assay for benralizumab: comparison with an antibody-dependent cell-mediated cytotoxicity (ADCC) cell-based assay. AAPS J 20:49.